CORONARY DISEASE
Conditions
Keywords
CORONARY DISEASE
Brief summary
The acute coronary syndrome (ACS) without ST elevation is a frequent pathology. The main evolutionary risk of these patients is the coronary thrombosis and its self complications. The platelets aggregation plays a major role in the physiopathology of the ACS. The therapeutic arsenal of the anti-thrombosis essentially resting on aspirin and heparin has been reinforced lately by the inhibitors of the glycoprotein anti GP IIb/IIIa. The profit of these products in the ACS with or without ST elevation, associated or not to coronarography, has clearly been demonstrated. This profit is more marked when patients are at high risk of complications. Thus, the use of an anti GP IIb/IIIa is recommended among patients at high risk for whom a coronarography is planned, in the last international recommendations of the European Cardiology Society (ESC), the American Heart Association and the American College of Chest Physician. Otherwise, some authors have proposed An early invasive strategy based on coronarography with discordant results. The ideal delay of realization of this coronarography is unknown. It varies according to the studies between 2.5 hours to 48 hours. Once again, patients at high risk seem to benefit the more of such a strategy if it is set precociously. Objective To compare an invasive strategy associating an early administration of tirofiban and a coronarography achieved in the 6 hours after the randomization to a conservative strategy in a population of high risk patients with ACS without ST elevation. Design Multicentric, prospective, randomized study.
Detailed description
Patient's selection Patient of more than 18 years with a ACS defined by a thoracic pain of more than 20 minutes that occurred during the last 24 hours, anomalies on EKG and one of the following criteria : diabetes; recurrence of coronary pain; precocious pain post-myocardial infarction; falling of the ST segment of \> 1 mm; transient elevation of the ST segment \> 1 mm; elevation of the I troponin, T troponin or CPK MB; hemodynamic instability; ventricular arrhythmia; TIMI score \> 5 Therapeutic modes All patients receive : aspirin, clopidogrel, enoxaparine. Trinitrin and analgesics are at the clinician's appreciation. Besides, either they receive an anti GP IIb/IIIa: tirofiban (Agrastat®) and are oriented in cardiology to have a coronarography in the six hours or they are oriented in cardiology to receive the classical treatment, guided by the investigations searching for signs of myocardial ischemia.
Interventions
intravenous infusion
standard procedure of coronarography
Sponsors
Study design
Eligibility
Inclusion criteria
* High risk ACS without ST elevation
Exclusion criteria
* Age \<18 years * Pregnancy * Persistence of the ST elevation * Recent left branch block * Cardiac failure or cardiogenic shock (Kilip 3 or 4) * Treatment by anti-vitamin K * Contra-indication to the use of one of the following treatments: aspirin, clopidogrel, enoxaparine, anti GP IIb/IIIa (tirofiban)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality, Myocardial Infarction and Revascularization in Emergency | d30 |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic Failure (Well Defined) During the First 6 Hours. Clinical Evolution and Electrocardiography | until the exit from the hospital and at d30. |
| Coronarographic Criteria : TIMI Score at the Beginning and the End of the Procedure; Existence of an Intra-coronary Thrombus | d30 |
| Troponin Peak. Left Ventricular Ejection Fraction Before Hospital Exit. Length of Stay in USIC and Hospital. Hemorrhagic Complications. | d30 |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Early Invasive Strategy Tirofiban and coronarography within six hours | 83 |
| Delayed Invasive Strategy Coronarography after six hours | 86 |
| Total | 169 |
Baseline characteristics
| Characteristic | Early Invasive Strategy | Total | Delayed Invasive Strategy |
|---|---|---|---|
| Age, Continuous | 63.9 years | 65.3 years | 66.5 years |
| BMI | 27.0 kg/m2 | 26.6 kg/m2 | 26.6 kg/m2 |
| Current smoker No | 39 participants | 84 participants | 45 participants |
| Current smoker Yes | 44 participants | 85 participants | 41 participants |
| Diabetes mellitus No | 48 participants | 106 participants | 58 participants |
| Diabetes mellitus Yes | 35 participants | 63 participants | 28 participants |
| Dyslipidemia No | 38 participants | 79 participants | 41 participants |
| Dyslipidemia Yes | 45 participants | 90 participants | 45 participants |
| Family history of CVS disease No | 63 participants | 127 participants | 64 participants |
| Family history of CVS disease Yes | 20 participants | 42 participants | 22 participants |
| Hypertension No | 33 participants | 68 participants | 35 participants |
| Hypertension Yes | 50 participants | 101 participants | 51 participants |
| On aspirin No | 44 participants | 98 participants | 54 participants |
| On aspirin Yes | 39 participants | 71 participants | 32 participants |
| Previous CABG No | 75 participants | 157 participants | 82 participants |
| Previous CABG Yes | 8 participants | 12 participants | 4 participants |
| Previous MI No | 64 participants | 130 participants | 66 participants |
| Previous MI Yes | 19 participants | 39 participants | 20 participants |
| Previous PCI No | 63 participants | 131 participants | 68 participants |
| Previous PCI Yes | 20 participants | 38 participants | 18 participants |
| Sex: Female, Male Female | 25 Participants | 48 Participants | 23 Participants |
| Sex: Female, Male Male | 58 Participants | 121 Participants | 63 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 83 | 0 / 86 |
| serious Total, serious adverse events | 2 / 83 | 1 / 86 |
Outcome results
Mortality, Myocardial Infarction and Revascularization in Emergency
Time frame: d30
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Early Invasive Strategy | Mortality, Myocardial Infarction and Revascularization in Emergency | 2 participants |
| Delayed Invasive Strategy | Mortality, Myocardial Infarction and Revascularization in Emergency | 21 participants |
Coronarographic Criteria : TIMI Score at the Beginning and the End of the Procedure; Existence of an Intra-coronary Thrombus
Time frame: d30
Therapeutic Failure (Well Defined) During the First 6 Hours. Clinical Evolution and Electrocardiography
Time frame: until the exit from the hospital and at d30.
Troponin Peak. Left Ventricular Ejection Fraction Before Hospital Exit. Length of Stay in USIC and Hospital. Hemorrhagic Complications.
Time frame: d30